TY - JOUR
T1 - Mesenchymal stem cell therapy for inflammatory bowel disease
T2 - A systematic review and meta-analysis
AU - Dave, Maneesh
AU - Mehta, Kathan
AU - Luther, Jay
AU - Baruah, Anushka
AU - Dietz, Allan B.
AU - Faubion, William A.
N1 - Publisher Copyright:
© 2015 Crohn's & Colitis Foundation of America, Inc.
PY - 2015/7/25
Y1 - 2015/7/25
N2 - Recent advances in inflammatory bowel disease (IBD) therapeutics include novel medical, surgical, and endoscopic treatments. Among these, stem cell therapy is still in its infancy, although multiple studies suggest that the immunomodulatory effect of stem cell therapy may reduce inflammation and tissue injury in patients with IBD. This review discusses the novel avenue of stem cell therapy and its potential role in the management of ulcerative colitis and Crohn's disease. We conducted a comprehensive literature search to identify studies examining the role of stem cell therapy (without conditioning and immunomodulatory regimens) in IBD. Taken together, these studies suggest a promising role for stem cell therapy in IBD although the substantial challenges, such as cost and inadequate/incomplete characterization of effect, limit their current use in clinical practice.
AB - Recent advances in inflammatory bowel disease (IBD) therapeutics include novel medical, surgical, and endoscopic treatments. Among these, stem cell therapy is still in its infancy, although multiple studies suggest that the immunomodulatory effect of stem cell therapy may reduce inflammation and tissue injury in patients with IBD. This review discusses the novel avenue of stem cell therapy and its potential role in the management of ulcerative colitis and Crohn's disease. We conducted a comprehensive literature search to identify studies examining the role of stem cell therapy (without conditioning and immunomodulatory regimens) in IBD. Taken together, these studies suggest a promising role for stem cell therapy in IBD although the substantial challenges, such as cost and inadequate/incomplete characterization of effect, limit their current use in clinical practice.
KW - adverse effects
KW - efficacy
KW - inflammatory bowel disease
KW - mesenchymal stem cells
KW - systematic review and meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=84945249500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945249500&partnerID=8YFLogxK
U2 - 10.1097/MIB.0000000000000543
DO - 10.1097/MIB.0000000000000543
M3 - Review article
C2 - 26230863
AN - SCOPUS:84945249500
SN - 1078-0998
VL - 21
SP - 2696
EP - 2707
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 11
ER -